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Abstract: The ImplementatioN of perSonalized medicine In NSCLC 
in Central Europe: EGFR testing, Histopathology, and clinical feaTures 
(INSIGHT) observational study assessed both implementation of epi-
dermal growth factor receptor (EGFR) mutation testing and treatment 
of patients with advanced EGFR mutation-positive non–small-cell lung 
cancer (NSCLC) in a real-world setting in Central Europe. A total of 
1785 patients from 14 cancer centers of six Central European countries 
were enrolled. EGFR mutations were detected in tumors of 13.8% of 
the patients. More than 70% of patients with advanced EGFR mutation-
positive NSCLC received EGFR tyrosine kinase inhibitors as first-line 
therapy. The INSIGHT study demonstrated the establishment of EGFR 
mutation testing, a mutation rate consistent with other Caucasian patients 
populations, and adherence to current guidelines regarding treatment of 
patients with EGFR mutation-positive tumors in Central Europe.
Key Words: Targeted therapy, INSIGHT, EGFR mutations, 
Molecular analysis.
(J Thorac Oncol. 2015;10: 1370–1374)
Lung cancer incidence rates in Central European countries are among the highest worldwide.1 More than 80% of lung 
cancers in Central Europe are smoking-related. Non–small-
cell lung cancer (NSCLC) comprises approximately 80% of 
all lung cancers.
Although chemotherapy has been the mainstay of sys-
temic therapy for NSCLC for many years, targeted therapies 
have opened new therapeutic opportunities. Blockade of the 
epidermal growth factor receptor (EGFR) by monoclonal 
antibodies or tyrosine kinase inhibitors (TKIs) improved 
outcome in patients with advanced NSCLC.2,3 EGFR muta-
tions were identified in 2004 and shown to correlate with 
clinical response to EGFR-targeted TKIS (EGFR TKIs).4–6 
Patients with advanced EGFR mutation-positive NSCLC 
had better outcomes with EGFR TKIs than with first-line 
chemotherapy in terms of response rate, progression-free 
survival, and quality of life, and in case of afatinib, also 
of overall survival.7–14 These results led to the approval of 
EGFR TKIs for first-line therapy of patients with advanced 
EGFR mutation-positive NSCLC and to clinical practice 
guidelines recommending EGFR mutation testing for all 
patients with advanced adenocarcinomas and EGFR TKIs 
as the preferred first-line therapy for patients with EGFR 
mutations in their tumors.15–18 The present ImplementatioN 
of perSonalized medicine In NSCLC in Central Europe: 
EGFR testing, Histopathology, and clinical feaTures 
(INSIGHT) observational study assessed whether these 
recommendations are implemented in a real-world setting 
in routine practice in cancer centers of Central Europe.
PATIENTS AND METHODS
Centers and Patients
Fourteen cancer centers from six Central European 
countries participated in the INSIGHT observational study 
(Table 1). Patients with NSCLC, whose tumors had been 
tested for EGFR mutations between November 5, 2011 and 
June 30, 2013 independent of tumor stage, were eligible for 
enrollment. The study has been approved by local ethical com-
mittees, dependent on local regulatory requirements.
DOI: 10.1097/JTO.0000000000000621
Copyright © 2015 by the International Association for the Study of Lung Cancer
ISSN: 1556-0864/15/1009-1370
Epidermal Growth Factor Receptor Mutation-Positive  
Non–Small-Cell Lung Cancer in the Real-World  
Setting in Central Europe
The INSIGHT Study
Rodryg Ramlau, MD, PhD,* Tanja Cufer, MD, PhD,† Peter Berzinec, MD, PhD,‡ Rafal Dziadziuszko, MD, PhD, 
§Włodzimierz Olszewski, MD, PhD,║ Helmut Popper, MD,¶ Paolo Bajcic, MD,# Ladislav Dušek, PhD,** 
Zuzana Zbozinkova, MS,** and Robert Pirker, MD,†† on behalf of the INSIGHT study team
*Department of Oncology, Poznan University of Medical Sciences, Poznan, 
Poland; †University Clinic, Golnik, Slovenia; ‡Specialized Hospital of 
St Zoerardus Zobor, Nitra, Slovakia; §Medical University of Gdansk, 
Gdansk, ║The Maria Sklodowska-Curie Institute of Oncology, Warsaw, 
Poland; **Institute of Biostatistics and Analyses, Faculty of Medicine, 
Masaryk University, Brno, Czech Republic; ¶Medical University of 
Graz, Graz, #Boehringer Ingelheim RCV, Vienna, and ††Department of 
Medicine I, Medical University of Vienna, Vienna, Austria.
The study was designed by the members of the Steering committee: TC, PB, 
RD, WO, HP, PB, LD, ZZ and RP. All authors contributed to the acquisi-
tion and interpretation of data. The manuscript was prepared by PB, ZZ 
and RP, and its final version was approved by all authors.
Disclosure: Dr. Robert Pirker received speaker’s fee and honoraria for advisory 
boards from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Serono, 
Pfizer, Roche, and Synta. Dr. Tanja Cufer received honoraria for advisory 
boards from Boehringer Ingelheim and Pfizer. Dr. Rodryg Ramlau has 
received honoraria for advisory boards from Boehringer Ingelheim, Eli 
Lilly, and MSD. All other authors declare no conflict of interest.
This study was supported by an unrestricted grant from Boehringer Ingelheim 
RCV, Vienna, Austria.
Address for correspondence: Robert Pirker, MD, Department of Medicine 
I, Medical University of Vienna, Waehringer Guertel 18–20, A-1090 
Vienna, Austria. E-mail: robert.pirker@meduniwien.ac.at
BRIEF REPORT
Copyright © 2015 by the International Association for the Study of Lung Cancer
1371Copyright © 2015 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 10, Number 9, September 2015 EGFR Mutation-Positive NSCLC in the Real-World Setting
Pathological Diagnosis
Tumor samples were obtained at the time of diagnosis 
and were used for pathological diagnosis. Sample source, type 
of sample collection, type of pathological assessment, and 
pathological diagnosis were collected.
EGFR Mutation Analysis
Tumor samples, mostly obtained at the time of initial 
diagnosis, were used for EGFR mutation analysis by one of 
the established standard tests locally at the corresponding par-
ticipating centers. Data on testing methods and rates and types 
of mutations were collected.
Treatment
Data on systemic treatment were collected only for 
patients with advanced EGFR mutation-positive NSCLC.
Statistics
Standard descriptive statistics were used for the analysis. 
Median values supplemented by minimum and maximum val-
ues were used for continuous variables. Categorical data were 
described using absolute and relative values of categories.
RESULTS
A total of 1785 NSCLC patients were enrolled into the 
INSIGHT study (Table 1). The characteristics of these patients 
at the time of initial diagnosis were as follows (Table 2): age, 
median 64 years (range 23–93 years); 60.7% males, 39.3% 
females; 99.7% Caucasians; Eastern Cooperative Oncology 
Group performance status and smoking status are summarized 
in Table 2. The rate of never smokers was 7.6% among males 
and 30.7% among females (data not shown).
Sample sources, collection methods, and specimen types 
are shown in Figure 1. Samples were obtained from primary 
tumors, lymph nodes metastases, and distant metastases in 
85.7%, 2.6%, and 11.7% of the patients, respectively. Tumor 
specimens were mainly obtained by bronchoscopy, endobron-
chial ultrasound (EBUS)/endoscopic (esophageal) ultrasound 
(EUS), computed tomography-guided biopsy, or surgery. 
Pathological diagnosis was based on histology (with or with-
out cytology) in 82.2% and on cytology alone in 17.8% of the 
patients. The majority of patients (78.8%) had adenocarcino-
mas, whereas squamous-cell carcinomas, large-cell carcino-
mas, and NSCLC not otherwise specified were diagnosed in 
9.6%, 0.9%, and 10.9% of the patients, respectively (Table 2).
EGFR mutation testing was done by restriction frag-
ment length polymorphism analysis of polymerase chain 
reaction-amplified fragments (PCR-RFL), Sanger sequencing, 
Roche Cobas EGFR mutation test, high resolution melting, or 
another method (Fig. 2). EGFR mutations were detected in 
tumors of 247 (13.8%) patients (Fig. 3). The mutation rates 
for histological and cytological specimens were 14.6% and 
12.9%, respectively (data not shown). The types of mutations 
are shown in Figure 3. Exon 19 deletions were seen in 107 
(43.3%) patients and L858R point mutations in 70 (28.3%) 
patients. T790M mutations and exon 20 insertions were 
seen in three (1.2%) and nine (3.6%) patients, respectively. 
Positive mutation rates showed some variation (from 10.8% to 
26.7%) between centers, probably because of different patient 
TABLE 1.  Participating Centers
Country
No. 
 of Centers
No.  
of Patients
Austria 2 76
Czech Republic 3 373
Hungary 1 131
Poland 4 696
Slovakia 3 186
Slovenia 1 323
Total 14 1785
TABLE 2.  Patient Characteristics
Characteristicsa All Patients
EGFR Mutation-Positive 
Patients
N (%) 1785 (100) 247 (100)
Age at diagnosis
  Median, yr (min–max) 64 (23–93) 65 (31–89)
Gender, n (%)
  Males 1083 (60.7) 103 (41.7)
  Females 702 (39.3) 144 (58.3)
Race, n (%)
  Caucasian 1774 (99.7) 247 (100)
  Other 5 (0.3) 0 (0)
Smoking status, n (%)
  Current smoker 627 (35.2) 36 (14.6)
  Former smoker 725 (40.7) 88 (35.6)
  Never smoker 272 (15.2) 110 (44.5)
  Unknown 158 (8.9) 13 (5.3)
ECOG PS at diagnosis, n (%)
  PS 0 217 (12.2) 54 (21.9)
  PS 1 928 (52.0) 114 (46.2)
  PS 2 242 (13.6) 32 (13.0)
  PS 3 54 (3.0) 13 (5.3)
  PS 4 5 (0.2) 1 (0.4)
  PS 5b 7 (0.4) 0 (0)
  Unknown 332 (18.6) 46 (13.2)
Histology, n (%)
  Adenocarcinoma 1393 (78.8) 215 (87.4)
  Squamous-cell carcinoma 170 (9.6) 7 (2.8)
  Large-cell carcinoma 11 (0.6) 1 (0.4)
  Other 193 (10.9) 23 (9.3)
Tumor stage, n (%)
  I 132 (7.4) 20 (8.1)
  II 107 (6.0) 12 (4.9)
  III 419 (23.5) 36 (14.6)
  IV 965 (54.1) 169 (68.4)
  Unknown 162 (9.1) 10 (4.0)
aAll characteristics are known in more than 90% of patients, with the exception of 
ECOG PS.
bSeven patients died during the period of clinical assessment.
ECOG PS, Eastern Cooperative Oncology Group performance status
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selection criteria for EGFR mutation testing (data not shown). 
The mutation rate increased from 5.7% (36 of 627) in current 
smokers to 12.1% (88 of 725) in former smokers, to 40.4% 
(110 of 272) in never smokers, and to 8.1% (13 of 161) in 
patients with unknown smoking status (Table 2).
The characteristics of EGFR mutation-positive patients 
(n = 247) are summarized in Table 2. They were more fre-
quently females and never smokers and had adenocarcinomas 
in 87.4%. Median age and performance status were similar to 
those of the total study population.
Data on first-line systemic therapy were available for 
184 patients with advanced EGFR mutation-positive NSCLC 
(Fig. 4). In 152 (82.6%) patients, the mutation status was avail-
able before initiation of first-line therapy. The majority (77.6 
%) of these 152 patients was treated with gefitinib or erlotinib, 
and the remaining patients received chemotherapy as first-line 
systemic therapy. In 32 patients, first-line therapy was initiated 
before the EGFR mutation status had become known and con-
sisted of chemotherapy. None of these patients did receive first-
line therapy with EGFR TKI, but two patients were switched 
to EGFR TKI during first-line chemotherapy after the test 
results had revealed the presence of EGFR mutations in their 
tumors. When combining first-line and second-line treatments, 
80.4% of the patients received EGFR TKIs during the observa-
tion period (data not shown). Some differences in treatment 
strategies between the various centers (countries) have been 
observed as first-line treatment with EGFR TKIs ranged from 
23.8% to 87.5% of the patients (data not shown).
DISCUSSION
The INSIGHT study, enrolling 1785 patients from 14 
cancer centers of six Central European countries, represents 
one of the largest studies on EGFR mutation testing and sys-
temic treatment of patients with advanced EGFR mutation-
positive NSCLC in Caucasian patients in a real-world setting. 
The INSIGHT study demonstrated that, first, EGFR mutation 
testing has quickly been established, and second, that treatment 
of patients with mutation-positive tumors in most centers has 
been consistent with early clinical recommendations for treat-
ment of advanced EGFR mutation-positive NSCLC.15–18
The EGFR mutation rate of 13.8% is equal to the one 
reported for Caucasians in the EURTAC study11 and another 
study, which screened 297 patients.19 The pattern of muta-
tions seen in the INSIGHT study is also similar to those of 
2.6%11.7%
85.7%
Source*
*Evaluable data for 1450 patients 
Lymph node metastases
Primary tumour
N = 38
N = 1243
Distant metastases N = 169 Histologic
Cytologic
31.3%
50.9%
17.8%
Both
N = 907
N = 317
N = 558
Specimen type*Method of collection*
22.1
19.0
11.0
8.8
7.0
2.1
1.5
1.4
0.6
0.5
1.9
24.1
0% 25% 50%
% of patients
transbronchial biopsy
surgical biopsy
intraluminal biopsy (excision of
endobronchial tumor)
CT-guided transparietal biopsy
EBUS and/or EUS guided needle
biopsy
brush
fine needle biopsy without RTG
control
pleural effusion
mediastinoscopy / thoracoscopy
CT-guided bronchoscopic biopsy
bronchial lavage
Other
N=412
N=377
N=325
N=188
N=151
N=119
N=35
N=25
N=24
N=10
N=9
N=32
*Evaluable data for 1707 patients *Evaluable data for 1782 patients 
FIGURE 1.  Tumor samples. Data on tumor samples are provided with regard to their sources, collection methods, and patho-
logical analysis.
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FIGURE 2.  Test methods. The tests used for determination 
of epidermal growth factor receptor (EGFR) mutation status 
are shown.
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Western European patient populations. Although we cannot 
exclude some selection toward patients with higher likelihood 
of mutation-positive tumors, a major selection bias is unlikely 
to have occurred because the clinical characteristics of the 
INSIGHT patient population such as gender and smoking sta-
tus are similar to those of patients from recent randomized 
phase III trials such as the First-Line ErbituX in lung cancer 
(FLEX) trial.20
The implementation of EGFR mutation testing at 
the various centers has been achieved by close cooperation 
between treating physicians and pathologists and has been 
facilitated by educational meetings at national and inter-
national levels. Mutation testing was done by one of the 
standard tests available in the respective countries. Primary 
tumors were the most common sample source for mutation 
testing. This reflects the fact that diagnosis was based on 
bronchoscopy or computed tomography-guided biopsy in 
the majority of patients and is consistent with common prac-
tice in other countries.
The INSIGHT study demonstrated that most (80.4%) 
patients with advanced EGFR mutation-positive NSCLC were 
treated with EGFR TKIs during the observation period. The type 
of EGFR TKI used was dependent on the treatment setting and 
drug availability in the respective countries. Gefitinib was widely 
used in the first-line setting, whereas erlotinib was more usually 
used in the second-line setting. This pattern probably has been 
caused by the fact that erlotinib has been in clinical use for years 
as second-line or maintenance therapy independent of muta-
tion status, whereas gefitinib has been the first TKI approved for 
the first-line therapy of patients with EGFR mutation-positive 
tumors. As an important indicator of adherence to standards of 
care, none of the patients without documented EGFR mutations 
received first-line therapy with an EGFR TKI. Thus treatment 
of patients based on EGFR mutation status in Central European 
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FIGURE 3.  Epidermal growth factor 
receptor (EGFR) mutations. The rate 
and the types of EGFR mutations are 
shown.
First-line therapy in patients with advanced
EGFR mutation-positive NSCLC
 N=184 (100%)
EGFR test result obtained
before first-line initiation
N= 152 (82.6%)
First-line therapy N
Gefitinib 99 (53.8%)
Chemotherapy 31 (16.8%)
Erlotinib 19 (10.3%)
Chemotherapy+bevacizumab 3 (1.6%)
First-line therapy N
Chemotherapy 31 (16.8%)
Chemotherapy+bevacizumab 1 (0.5%)
EGFR test result obtained
after first-line initiation
N= 32 (17.4%)
FIGURE 4.  First-line treatment of epidermal growth 
factor receptor (EGFR) mutation-positive patients. 
Palliative first-line therapy has been assessed in184 
patients with EGFR mutation-positive non–small-cell 
lung cancer (NSCLC).
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cancer centers is consistent with current international guidelines. 
The INSIGHT findings were obtained from major cancer cen-
ters and similar information from smaller centers would also be 
of interest. This could be obtained through lung cancer registries 
which already exist in some countries, e.g., Czech Republic.
Timely access to approved novel drugs remains chal-
lenging in several participating countries and ranged from 122 
days in Austria to 550 days in the Czech Republic (Table 3).21 
For comparisons, the days were 118, 140, and 248 for the 
United Kingdom, Switzerland, and Finland, respectively 
(Table 3).21 Timely access in several Central European coun-
tries is particularly hindered by the slow process of reimburse-
ment, and a collaborative work might be helpful to speed up 
reimbursement procedures in individual countries.
Finally, the INSIGHT study also enhanced collabora-
tion among lung cancer experts of Central European coun-
tries, which will synergize joint efforts to decrease the high 
burden of lung cancer in Central Europe.
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